Cell therapy (CAR-T) · Kills target cells, directed at CD19
Phase 1Most advanced trial
1Registered trials
What is Azercabtagene Zapreleucel?
Azercabtagene zapreleucel is an allogeneic, off-the-shelf T-lymphocyte cell therapy genetically modified to express a chimeric antigen receptor targeting CD19, a B-cell surface antigen. The modified cells are designed to recognize and kill CD19-expressing B cells. It is being studied in B-cell mediated autoimmune disorders.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.